Modern Pathology

FIGURES AND TABLES

FROM:

Loss of BMI-1 expression is associated with clinical progress of malignant melanoma

Ingeborg M Bachmann, Hanne E Puntervoll, Arie P Otte and Lars A Akslen

BACK TO ARTICLE
Figure 1 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 1.

Western blot analysis of HeLa cell lysate confirming the specificity of the BMI-1 antibody (clone F6; Upstate).

Full figure and legend (33K)
Figure 2 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 2.

Immunoreactivity for BMI-1 in cutaneous melanoma of vertical growth phase, showing (a) strong and (b) negative protein expression for the F6 antibody.

Full figure and legend (258K)
Figure 3 - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Figure 3.

Patient survival by BMI-1 (C69) expression in nodular melanomas (Kaplan–Meier method).

Full figure and legend (19K)
Table 1 - Associations between tumor cell expression of BMI-1, using two different antibodies, and important clinico-pathological variables and biomarkers in nodular melanomas - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 1 - Associations between tumor cell expression of BMI-1, using two different antibodies, and important clinico-pathological variables and biomarkers in nodular melanomas.

Full table
Table 2 - Estimated 5- and 10-year survival rates for patients with vertical growth phase melanoma (product-limit method) by clinico-pathological variables, p16 and BMI-1 using death from melanoma as end point - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 2 - Estimated 5- and 10-year survival rates for patients with vertical growth phase melanoma (product-limit method) by clinico-pathological variables, p16 and BMI-1 using death from melanoma as end point.

Full table
Table 3 - Multivariate survival analysis (Cox proportional hazards method) for patients with vertical growth phase melanoma of the nodular subtype, using tumor-related death as end point - Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, please contact help@nature.com or the author

Table 3 - Multivariate survival analysis (Cox proportional hazards method) for patients with vertical growth phase melanoma of the nodular subtype, using tumor-related death as end point.

Full table
BACK TO ARTICLE